Clinical Trial Update: Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of a self-complementary AAV vector delivering factor IX for gene transfer in Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• scAAV-FIX gene therapy vector (self-complementary adeno-associated viral vector expressing coagulation factor IX)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Hemophilia B | Phase 1 | Status: COMPLETED